PMSF: Scope and Limits of Protease Inhibition

2026-10-13

Phenylmethanesulfonyl fluoride (PMSF) is an irreversible serine protease inhibitor used conceptually to limit proteolytic degradation in protein-extraction and immunoblotting contexts. Its selectivity is also its main boundary: PMSF does not broadly inhibit all protease classes, and supplier descriptions alone cannot establish performance across biological systems or experimental endpoints.

Phosphatase Inhibitor Cocktail: Evidence Scope

2026-10-13

APExBIO’s Phosphatase Inhibitor Cocktail (2 Tubes, 100X), SKU K1015, is documented as a two-component research reagent intended to limit endogenous phosphatase activity during protein sample handling. The available evidence is limited to supplier information; no matched research paper or independent performance data were provided.

SB 431542 in Mouse Corneal Cell Culture

2026-10-12

GSTM5, Genomic Stability and PLK1 in Breast Cancer

2026-10-12

A 2026 study combined genetic, epigenetic, transcriptomic and experimental evidence to prioritize GSTM5 as a breast-cancer susceptibility and genomic-stability candidate. Its findings support—but do not establish—a biomarker-informed hypothesis that GSTM5-low tumors may be more vulnerable to PLK1 inhibition.

Forskolin and Human Neurons in HSV-1 Latency

2026-10-11

Oh et al. developed and evaluated a human induced-pluripotent-stem-cell-derived sensory neuron model for HSV-1 latency and reactivation. The study supports the model as a scalable platform for investigating neuron-intrinsic mechanisms, while its findings do not establish Forskolin as an HSV treatment or demonstrate equivalence to infection in humans.

Wortmannin in PI3K Signaling and Cancer Research

2026-10-10

Wortmannin is a widely used research tool for interrogating PI3K-related signaling, but its irreversible action and reported activity against additional kinases require cautious interpretation. A 2026 hepatocellular carcinoma study connects FAT4 loss with PI3K/AKT activation, ferroptosis resistance, and sorafenib response, while also illustrating why pathway-level findings should not be attributed specifically to Wortmannin without direct compound evidence.

ERAD Hijacking for Transmembrane Protein Degradation

2026-10-09

Song and colleagues introduce ERAD-engaging chimeras (ERADECs), a targeted protein degradation strategy that recruits endoplasmic-reticulum-associated degradation to remove transmembrane proteins. The study identifies desonide as a SYVN1-binding chemical warhead and reports potent PD-L1 degradation, tumor-suppression activity, and an extension of the concept to mutant huntingtin.

Sildenafil Citrate: PDE5 Signaling and Proteoforms

2026-10-09

A source-grounded overview of Sildenafil Citrate research, linking PDE5–cGMP signaling and vascular biology with recent evidence on proteoform-specific drug interactions, retinal PDE6 off-target binding, and the limits of translating vendor-reported findings into broader therapeutic conclusions.

Sildenafil Citrate: Proteoform-Aware Evidence

2026-10-08

A source-grounded overview of Sildenafil Citrate research, linking PDE5 pharmacology with recent native mass-spectrometry findings on proteoform-specific interactions. The discussion separates established study observations from supplier-reported context, compares molecular and translational evidence, and defines limits for interpreting PDE6 binding, cGMP biology, vascular signaling, and potential visual off-target effects.

Phosphatase Inhibitor Cocktail 2 in PI3K/Akt Research

2026-10-08

A source-grounded overview of how Phosphatase Inhibitor Cocktail 2 may fit conceptually into phosphoprotein studies, using canine mammary gland tumor research to distinguish supplier claims from published evidence.

IBDV VP3 Disrupts IRF7 Antiviral Signaling

2026-10-07

A 2025 study links the IBDV VP3 protein to suppression and proteasome-associated degradation of chicken IRF7, a key regulator of type I interferon responses. The findings provide a mechanistic framework for viral immune evasion while remaining primarily cell-based and requiring validation in broader infection models.

Bergeyella cardium and Floatptosis in Macrophages

2026-10-07

A 2025 Cell Discovery study identifies floatptosis, a lysosome-fusion-associated form of cytoplasmic vacuolization cell death triggered by a Bergeyella cardium variant in macrophages. The work connects this phenotype to outer membrane vesicles, barrel-like proteins, amiloride-sensitive signaling, and SLC9A9-dependent vacuole fusion while defining important boundaries for interpreting related autophagy and PI3K studies.

From Lysate Integrity to Translational Signal

2026-10-06

A mechanistic and translational perspective on how protease control can strengthen interpretation of liver-injury and phospho-signaling studies, using recent lanthanum hepatotoxicity research as a case study.

Phosphatase Inhibitor Cocktail 2: Five Key Questions

2026-10-06

A source-grounded overview of how phosphatase inhibition supports protein phosphorylation preservation, what the Nguyen et al. mouse study does and does not show, and where product claims require cautious interpretation.

LY294002 in PI3K/Akt Signaling Research

2026-10-05

This source-grounded overview examines LY294002, also known as 2-(4-Morpholinyl)-8-phenyl-4H-l-benzopyran-4-one, as a research probe for PI3K/Akt/mTOR signaling. It places the compound in the context of a 2024 study of colitis-associated colorectal cancer, where LY294002 was one pharmacological antagonist used to interrogate signaling linked to macrophage polarization. The evidence supports a hypothesis-generating role for PI3K-related signaling but does not establish LY294002 as a selective therapeutic or prove that PI3K inhibition alone caused the reported effects.